Sanford Burnham Prebys researchers determined that boosting levels of SORLA protects critical brain cell connections and reduces neurodegenerative damage in mice. The protein was shown to decrease tau hyperphosphorylation, which prevents the proteins from clumping together and spreading aggregates. Crucially, the experiments revealed that elevating SORLA preserved vital synapses and synaptic plasticity responsible for supporting memory and learning. Lead researcher Timothy Huang noted that these findings demonstrate the molecule's ability to counter tau tangles in addition to amyloid-beta plaques.
Key points
The protein SORLA targets both toxic tau tangles and amyloid-beta plaques to combat neuro…: The protein SORLA targets both toxic tau tangles and amyloid-beta plaques to combat neurodegenerative decline.
Enhancing SORLA helps preserve vital synapses and synaptic plasticity essential for learn…: Enhancing SORLA helps preserve vital synapses and synaptic plasticity essential for learning and memory functions.
Boosting natural brain defenses through this protein offers a viable pathway for future A…: Boosting natural brain defenses through this protein offers a viable pathway for future Alzheimer's therapies.
Sources checked by our analysis pipeline: 1
- Date:
- November 18, 2026
- Source:
- Sanford Burnham Prebys
- Summary:
- Scientists have uncovered a powerful natural defense against Alzheimer’s disease that could open the door to new treatments. By boosting a protein called SORLA, researchers significantly reduced toxic tau tangles, protected connections between brain cells, and prevented some of the brain shrinkage associated with neurodegeneration in mice. Removing the protein made the damage worse, highlighting its critical protective role.
- Share:
A protein that helps protect the brain may offer scientists a promising new way to fight Alzheimer's disease and other forms of dementia. Researchers have discovered that increasing levels of this protein can reduce the buildup of toxic tangles associated with brain damage, while also helping preserve the connections that allow nerve cells to communicate.
The findings, published in Science Advances by scientists at Sanford Burnham Prebys, suggest that strengthening the brain's own protective mechanisms could eventually lead to new treatments for neurodegenerative diseases. In experiments with mice, the researchers found that boosting the protein reduced several damaging changes associated with Alzheimer's, including brain…
Federal regulators have provided detailed explanations regarding their decision to decline approval for Summit's pharmaceutical candidate. The move delivers critical regulatory clarity for the biotechnology sector as companies monitor agency review standards. Meanwhile, leadership at the regulatory body faces ongoing uncertainty following sudden executive staffing shifts.
Resistance from conservative lawmakers over controversial public health stances has derailed the administration's planned leadership pick for the nation's primary drug regulator. Meanwhile, clinical trial safety and efficacy concerns have forced a major pharmaceutical manufacturer to abandon an entire late-stage blood cancer program. These parallel setbacks disrupt both federal healthcare policy planning and corporate oncology pipelines.
Healthcare teams are turning to rhythmic physical therapy to tackle motor symptoms that traditional pharmaceuticals often fail to control. Starting in February 2027, the hospital will formally integrate these music-led sessions to help individuals bypass damaged neural pathways, reduce freezing episodes, and improve coordination. The clinical initiative responds directly to a surging caseload of patients diagnosed with the progressive neurological condition.